Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
Published
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence’s Chairman of the
Full Article